INV 101 - Innovo Therapeutics
Alternative Names: INV-101 - Innovo TherapeuticsLatest Information Update: 24 Dec 2022
At a glance
- Originator Innovo Therapeutics
- Class Anti-inflammatories; Small molecules
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Ulcerative colitis
Most Recent Events
- 21 Apr 2022 Phase-I clinical trials in Ulcerative colitis (In volunteers) in USA (PO) (NCT05844592)
- 31 Mar 2022 Innovo Therapeutics approves IND application in ulcerative colitis by the US FDA (Innovo Therapeutics pipeline, December 2022)